Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. - Wikidata - wikimedia - TriplyDB

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.

http://www.wikidata.org/entity/Q37231972

about

Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets Melanoma Brain Metastasis: Mechanisms, Models, and Medicine Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.High intensity focused ultrasound inhibits melanoma cell migration and metastasis through attenuating microRNA-21-mediated PTEN suppression.Transmigration characteristics of breast cancer and melanoma cells through the brain endothelium: Role of Rac and PI3K.[Melanoma brain metastases : Treatment options].Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases Melanoma metastases caught in the AKT Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid Expression of Phosphatase and Tensin Homologue, phospho-Akt, and p53 in Acral Benign and Malignant Melanocytic Neoplasms (Benign Nevi, Dysplastic Nevi, and Acral Melanomas)Pathologic and gene expression features of metastatic melanomas to the brain Synergistic anti-glioma effect of a coloaded nano-drug delivery system.Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology.Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.Molecular insights into melanoma brain metastases.Melanoma Brain Metastases: Current Areas of Investigation and Future Directions.Melanoma central nervous system metastases: current approaches, challenges, and opportunities.Metastasis as an evolutionary process.The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.Melanoma tumors frequently acquire LRP2/megalin expression, which modulates melanoma cell proliferation and survival rates.Converting biology into clinical benefit: lessons learned from BRAF inhibitors.Tumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells.Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN Leptomeningeal Disease and the Evolving Role of Molecular Targeted Therapy and Immunotherapy.The biology and therapeutic management of melanoma brain metastases.Herbacetin suppresses cutaneous squamous cell carcinoma and melanoma cell growth by targeting AKT and ODC.Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.Foe or friend? Janus-faces of the neurovascular unit in the formation of brain metastases.Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era.Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?Targeting the duality of cancer.[Tumor Cells and Micro-environment in Brain Metastases].Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter

P2860

Q26795735-3B786F78-BD4B-40C6-9646-0533248A147C Q28069421-05FDF1D9-D664-4EA2-B16D-541BE1EAF3CF Q30251581-FB939B58-2018-45D1-9BF7-00C07DE4644D Q30277902-C4593234-A4A0-443B-9E78-EBB7092286FB Q30365568-84CCEA00-210E-480B-8C67-0662391BD61C Q30787310-26DAFE88-1E23-4618-84D6-FA8B62D53F78 Q31098294-137F86B8-BFF9-4408-9483-873B0D92C817 Q34438536-12DC5622-9E75-4FDB-9F52-38FF1353B2E3 Q34438555-653803A0-15AC-47C6-BC24-B50B27E9448D Q34473662-A6A99283-1232-49F9-811B-120FE95455D8 Q35820476-458748AA-9D3F-46EF-A381-5E2E6B9990C1 Q36274943-E66807E5-2BAD-43F4-A209-2CA43B9CACEC Q36533041-B25FEDFC-B1A7-49E9-89FB-61F5B5B8158F Q36998064-E09F0C2A-DD8F-4CC2-B1F3-59A262900151 Q37168845-AA4C010C-15B8-4A6A-931F-B5F9081C6928 Q37339357-C8954B02-8361-4A4A-A574-73C08A079543 Q37512029-BC4326C5-37AA-445C-81CC-F1CF5EF24F91 Q37527883-367974AC-2F39-4DED-922A-F4A624410AA5 Q37707106-783591BE-B5A7-40B7-ADDB-678F3EC18C00 Q38148747-48558A5A-C474-482E-A770-FC30B5268092 Q38737680-E783E443-2BDC-4096-BD82-09B023E7F3C2 Q38764364-2ADD13E1-1D7F-466D-AFB4-9F6F1387F078 Q38766796-02B0069C-31CC-40EB-A1B8-F70B29153105 Q38807942-B6493474-7333-443E-8054-FF95A237D784 Q38819909-720DFFA3-971F-4669-B07A-97E7E5AB8F1E Q38909389-A54AA884-C9D9-43F4-BE4F-B31F766F23D5 Q38920389-9720BD89-FCAE-49C8-BBEC-6E958B5E6340 Q38940098-88A836A8-2353-47FD-BA16-F41C70473B85 Q39924257-E6FF2FCA-9D91-436A-BE63-4058CC7BB3FB Q41593039-7366C55D-20C7-4DE9-B354-6CFCB27FBA32 Q47133535-93C9C500-D532-4FD0-950A-2E1FB6D62826 Q47247953-FBAB97E0-FB80-497C-8F30-1C869552B843 Q47613853-118682EE-A553-4CD3-AA83-8E4FF3C03FC0 Q47653459-871254A2-6375-4343-B663-BAC9D5A9DF67 Q48108646-83BE2754-E365-4F45-86D0-1233FD898D68 Q48234725-7FB54369-73B3-4357-8227-D8A6B1CDD039 Q50043843-6DC4B751-7310-4EA9-97FD-E9200D142A22 Q52539731-78BB8562-E2FE-4747-AFE0-D5063A796444 Q53022125-EB0A5BB4-FE14-4CFB-9B0B-B78D574F2F51 Q56673276-E95F8AAF-562B-40A0-AD1A-4BA4F59B6328

P2860

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.

http://www.wikidata.org/entity/Q37231972

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 February 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting hyperactivation of t ...... of melanoma brain metastases.

@en

Targeting hyperactivation of t ...... of melanoma brain metastases.

@nl

type

label

Targeting hyperactivation of t ...... of melanoma brain metastases.

@en

Targeting hyperactivation of t ...... of melanoma brain metastases.

@nl

prefLabel

Targeting hyperactivation of t ...... of melanoma brain metastases.

@en

Targeting hyperactivation of t ...... of melanoma brain metastases.

@nl

P1433

Q37231972-66B1DB1C-CE12-4D2C-A1AC-0B6036F6AB31

P1476

Q37231972-DD35DC85-808B-402A-9F5F-05C39A160E64

P2093

Q37231972-18841A40-721A-495D-BABF-CBFF1FCC31D6

Q37231972-1BB88318-2F91-4C31-A42F-90F2981EC505

Q37231972-21923B86-6DC2-49EE-AB42-B0340BE5B18B

Q37231972-2224EAB1-F08B-4F84-9C7A-EFB830115BB8

Q37231972-2381EBD5-9440-4D55-A13D-773F39CB166B

Q37231972-266BB943-F50E-409D-9E1B-2D9A29D24763

Q37231972-3056BB15-38B3-458E-B433-B0216C1E14DC

Q37231972-361880C8-8CF5-453E-AB61-708E5C3FBD41

Q37231972-38454458-643F-4665-9442-23730A1AFA08

Q37231972-451758F7-4F80-4257-830E-1723772235A5

P2860

Q37231972-00FF881D-B117-43F7-A1DE-037ADF5EFEBB

Q37231972-1401F93B-EB5B-4C06-AD7B-979E7746081D

Q37231972-24CC1430-0FDF-4E40-B4A7-F6FB1DDA1733

Q37231972-404CC40E-22D0-4811-90C3-D9962CCB5FEF

Q37231972-47A39121-9AAE-47CE-A5E1-C5C51B7B0AEF

Q37231972-47C5BFF3-10F4-4657-A295-52E5D761EB5B

Q37231972-51479949-5241-42FE-A1B8-CF636D4609DC

Q37231972-537F0572-6386-4C1F-A31A-20873272DBAA

Q37231972-56120301-C252-4F2E-ABA1-C981E4047BB4

Q37231972-6E000D00-E53C-4D77-B7F6-7D966B71DB6B

P304

Q37231972-50F209FD-86CA-45E5-BC0D-A986730E2B93

P31

Q37231972-DDE63DD7-8311-4DD2-83F3-C7B161505C04

P356

Q37231972-72EDD668-5275-44F9-84B7-CC9C5094DDBD

P407

Q37231972-332F2E5A-BD58-444E-8C10-E51D1FB7543D

P433

Q37231972-5E29DB67-C18E-4D71-82FD-1F5828FD409E

P478

Q37231972-EF285644-124B-4F48-8528-3E370288C91B

P50

Q37231972-AA91F568-C71F-492B-93D0-C7F92858FF96

Q37231972-B1458F15-11F9-47FB-B049-4BFC40B685D5

Q37231972-B6B457D6-F3CF-461A-B1B2-EEF1E4A090F5

Q37231972-F7764859-A7C0-44DF-ADC5-04FD6112725B

P577

Q37231972-BF424997-827D-46A9-97C1-87B14A138B7D

P5875

Q37231972-4286B177-97FA-42BB-BDCC-A4A6A5B1C84C

P698

Q37231972-FBCE726C-DE37-4500-B24D-AF492B61EC3E

P932

Q37231972-212B81EE-CE92-4F48-8A82-8FA20524F856

P356

P1433

Cancer Medicine

P1476

Targeting hyperactivation of t ...... of melanoma brain metastases.

@en

P2093

Alexander Roesch

http://www.w3.org/2001/XMLSchema#string

Andrea Forschner

http://www.w3.org/2001/XMLSchema#string

Annemarie Adam

http://www.w3.org/2001/XMLSchema#string

Antje Bornemann

http://www.w3.org/2001/XMLSchema#string

Benjamin Weide

http://www.w3.org/2001/XMLSchema#string

Bernhard Klumpp

http://www.w3.org/2001/XMLSchema#string

Claus Garbe

http://www.w3.org/2001/XMLSchema#string

Cornelia Mauch

http://www.w3.org/2001/XMLSchema#string

Dagmar Kulms

http://www.w3.org/2001/XMLSchema#string

Daniela Beck

http://www.w3.org/2001/XMLSchema#string

P2860

Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Mutations of the BRAF gene in human cancer

Final version of 2009 AJCC melanoma staging and classification

Determinants of survival in patients with brain metastases from cutaneous melanoma.

Deregulated Akt3 activity promotes development of malignant melanoma.

Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis

Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm.

Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.

P304

76-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.50

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Dirk Schadendorf

Leticia Quintanilla-Martinez

Ghazaleh Tabatabai

P577

2013-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233919779

http://www.w3.org/2001/XMLSchema#string

P698

24133630

http://www.w3.org/2001/XMLSchema#string

P932

3797558

http://www.w3.org/2001/XMLSchema#string